Management of osteoporosis in women with breast cancer

IF 0.4 Q4 ONCOLOGY

Breast Cancer Management Pub Date : 2020-06-01 DOI:10.2217/bmt-2020-0012

C. Shapiro

引用次数: 4

Abstract

The screening, prevention and treatment of osteoporosis are similar in women with or without breast cancer. Breast cancer treatments, such as aromatase inhibitors, chemotherapy-induced ovarian failure and gonadotropin-releasing hormone antagonists all decrease estrogen levels, which in turn causes net bone resorption and bone loss. Bone loss over time will be of sufficient magnitude to cause some women to experience fractures. Thus, osteoporosis is an equation; the peak bone mass achieved by age 30 years minus the age-related and menopausal bone loss. Women should have their bone density measured by dual x-ray absorptiometry scans every 2 years. As clinically indicated, women should receive anti-osteoporosis drugs such as zoledronic acid, denosumab or oral bisphosphonates.

查看原文本刊更多论文

癌症妇女骨质疏松症的治疗

患有或不患有癌症的妇女骨质疏松症的筛查、预防和治疗是相似的。乳腺癌症治疗，如芳香化酶抑制剂、化疗诱导的卵巢衰竭和促性腺激素释放激素拮抗剂，都会降低雌激素水平，从而导致净骨吸收和骨丢失。随着时间的推移，骨质流失的程度足以导致一些女性骨折。因此，骨质疏松症是一个方程式；30岁时达到的峰值骨量减去与年龄相关的和更年期的骨质损失。女性应每两年通过双x射线吸收仪扫描测量一次骨密度。如临床所示，妇女应服用抗骨质疏松药物，如唑来膦酸、地诺舒单抗或口服双膦酸盐。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

Breast Cancer Management ONCOLOGY-

CiteScore

0.60

自引率

0.00%

发文量

审稿时长

13 weeks

期刊介绍： Breast Cancer Management (ISSN: 1758-1923) addresses key issues in disease management by exploring the best patient-centered clinical research and presenting this information both directly, as clinical findings, and in practice-oriented formats of direct relevance in the clinic. The journal also highlights significant advances in basic and translational research, and places them in context for future therapy. Breast Cancer Management provides oncologists and other health professionals with the latest findings and opinions on reducing the burden of this widespread disease. Recent research findings and advances clinical practice in the field are reported and analyzed by international experts. The journal presents this information in clear, accessible formats. All articles are subject to independent review by a minimum of three independent experts. Unsolicited article proposals are welcomed and authors are required to comply fully with the journal’s Disclosure & Conflict of Interest Policy as well as major publishing guidelines, including ICMJE and GPP3. Coverage includes: Diagnosis and imaging, Surgical approaches, Radiotherapy, Systemic therapies, Cancer clinical trials, Genetic aspects of disease, Personalized medicine, Translational research and biomarker studies, Management of psychological distress, Epidemiological studies, Pharmacoeconomics, Evidence-based treatment guidelines.